KALV vs. IBRX, BHC, CPRX, TARS, IDYA, BEAM, CDTX, IRON, AGIO, and TVTX
Should you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include ImmunityBio (IBRX), Bausch Health Cos (BHC), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.
KalVista Pharmaceuticals vs. Its Competitors
KalVista Pharmaceuticals (NASDAQ:KALV) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
8.6% of ImmunityBio shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 76.8% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
KalVista Pharmaceuticals has a net margin of 0.00% compared to ImmunityBio's net margin of -648.57%. ImmunityBio's return on equity of 0.00% beat KalVista Pharmaceuticals' return on equity.
KalVista Pharmaceuticals has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
KalVista Pharmaceuticals presently has a consensus price target of $26.43, suggesting a potential upside of 123.03%. ImmunityBio has a consensus price target of $10.75, suggesting a potential upside of 323.23%. Given ImmunityBio's higher possible upside, analysts clearly believe ImmunityBio is more favorable than KalVista Pharmaceuticals.
KalVista Pharmaceuticals has a beta of -0.15, meaning that its share price is 115% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.
In the previous week, ImmunityBio had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 4 mentions for ImmunityBio and 2 mentions for KalVista Pharmaceuticals. ImmunityBio's average media sentiment score of 0.89 beat KalVista Pharmaceuticals' score of 0.55 indicating that ImmunityBio is being referred to more favorably in the news media.
Summary
ImmunityBio beats KalVista Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get KalVista Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KalVista Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:KALV) was last updated on 10/4/2025 by MarketBeat.com Staff
